Horizon Pharma completes sale of European marketing rights for PROCYSBI(R)
Horizon Pharma announced it has completed the sale of a European subsidiary that owns the marketing rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ in EMEA regions to Chiesi Farmaceutici for an upfront payment of $72.2 million, plus milestone payments. June 23, 2017